SLIM LIVER: Semaglutide and HIV

A 2026 secondary analysis of SLIM LIVER found that a blood-based liver severity category improved in 31% of 36 selected weight-loss responders after 24 weeks of semaglutide treatment. Sixty-one percent stayed in the same category, while 8% moved to a worse category. No liver biopsies were taken. These results concern a serum metabolomics panel, not direct proof that inflammation or scarring resolved^[1][2].

The parent study was a small, open-label, single-arm phase 2 trial that enrolled 51 people living with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD). In the 48-person per-protocol analysis at week 24, mean liver fat fell by 31.33% relative to baseline, and 14 participants no longer met the study's MRI threshold for MASLD^[3].

What the 2026 analysis measured

Lake and colleagues used the OWLiver serum panel, which applies three sequential metabolomics algorithms to molecules in blood. The panel sorts results into no MASLD, MASLD without metabolic dysfunction-associated steatohepatitis (MASH), MASH, or at-risk MASH. It offers a non-invasive estimate, but it is not the same as examining liver tissue^[2].

The researchers tested stored serum from 36 US participants who completed the study per protocol and lost more than 2.27 kg. The category result was mixed. Eleven moved to a better OWLiver category, 22 stayed in the same category, and three moved to a worse one. The authors described the overall pattern as suggesting histologic improvement, but that suggestion was not checked against biopsies^[2].

The analysis excluded ten weight-loss non-responders and two Brazilian participants because their samples could not be transferred. It therefore shows what happened to this blood score in a selected responder group, not the average result for everyone who starts semaglutide.

The NIH funded the work, with supplementary support from UTHealth Houston. One author was an employee of Rubió Metabolomics, the laboratory that performed the OWLiver assays. That disclosure does not negate the measurements, but it matters when interpreting a paper about the panel's possible clinical use^[2].

The original SLIM LIVER result

SLIM LIVER, registered as ACTG A5371 and NCT04216589, studied adults with suppressed HIV on antiretroviral therapy. Participants also had central adiposity, insulin resistance or prediabetes, and at least 5% liver fat measured by MRI. Everyone received weekly subcutaneous semaglutide for 24 weeks. No participant received placebo^[3].

In the 48-person per-protocol analysis, mean liver fat fell by 4.24 percentage points, a 31.33% relative reduction. Mean body weight fell by 7.8 kg, and 14 participants had liver fat below 5% at week 24. These are changes within one treated group, so they cannot show how much would have changed without treatment^[3].

The registry records 51 treated participants, no deaths, and two serious events during follow-up. Its event table does not show that either event was caused by semaglutide. Uncommon risks remain uncertain here^[3].

Why MASLD and MASH are different claims

MASLD describes excess liver fat in a person with at least one cardiometabolic risk factor. MASH adds inflammation and liver-cell injury, with or without fibrosis. MRI can quantify liver fat, while OWLiver estimates disease severity from blood metabolites. Neither measurement in this study directly observed inflammation or fibrosis in a biopsy sample^[2][3].

The paper's title can be read more strongly than its methods allow. The report supports category improvement in 11 selected responders. It does not report biopsy-confirmed MASH resolution, fibrosis improvement, or fewer cases of cirrhosis. Its abstract says the results are "suggesting histologic improvements"^[1][2].

The newer analysis also cannot separate a direct liver effect from the effect of weight loss. Every participant had crossed the prespecified weight-loss threshold and there was no untreated comparison group, so a controlled trial with broader enrolment and direct clinical or biopsy outcomes would be needed to test that question.

What this means for people with HIV

SLIM LIVER was designed for people with HIV, rather than using a subgroup from a general obesity trial. Participants had suppressed HIV, metabolic risk, and MRI-confirmed liver fat. That makes the cohort relevant, while the single-group design still limits the conclusion^[3].

The study does not establish a treatment pathway for an individual patient. Semaglutide is a prescription medicine with different licensed indications across jurisdictions. Readers can review the broader evidence and safety context on our semaglutide overview and check its linked regulatory section. HIV treatment, other medicines, liver status, and metabolic risk belong in a clinician-led decision.

What we don't yet know

The strongest parent-study finding remains the MRI result: liver fat moved down over 24 weeks in a small treated cohort. The 2026 paper adds a metabolomics signal that improved for 11 of 36 selected responders, stayed unchanged for most, and worsened for three. Agreement between non-invasive measures can inform future research, but it does not replace randomization, a control group, or direct measurement of liver inflammation and fibrosis^[2][3].

Longer controlled studies need to show whether the changes persist, apply to people who lose little or no weight, and translate into fewer serious liver outcomes. Until then, SLIM LIVER is an encouraging phase 2 signal with clear limits, not confirmation that semaglutide reverses MASH in people with HIV.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.